Register Login

ATEA PHARMACEUTICALS, INC. (AVIR)

SymbolAVIR
NameATEA PHARMACEUTICALS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address125 SUMMER STREET, BOSTON, Massachusetts, 02110, United States
Telephone+1 857 284-8891
Fax—
Email—
Websitehttps://www.ateapharma.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK—
Description

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The companys medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.

Additional info from NASDAQ:
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The companys medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.

2026-03-26 17:11

New Form SCHEDULE 13G/A - Atea Pharmaceuticals, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000786 <b>Size:</b> 7 KB

Read more
2026-03-24 12:00

ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO

Read more
2026-03-13 22:00

Corcoran Andrea 🟢 acquired 120.0K shares (1 derivative) of Atea Pharmaceuticals, Inc. (AVIR) at $1.24 Transaction Date: Mar 11, 2026 | Filing ID: 106547

Read more
2026-03-05 21:11

(10% Negative) ATEA PHARMACEUTICALS, INC. (AVIR) Announces Delay in results Trials for serious viral diseases Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Read more
2026-03-05 21:05

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Read more
2026-02-26 12:00

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

Read more
2026-02-24 12:00

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Read more
2026-02-09 16:02

New Form SCHEDULE 13G - Atea Pharmaceuticals, Inc. <b>Filed:</b> 2026-02-09 <b>AccNo:</b> 0001373604-26-000010 <b>Size:</b> 7 KB

Read more
2026-02-04 00:53

Horga Maria Arantxa 🟡 adjusted position in 157.4K shares (3 derivative) of Atea Pharmaceuticals, Inc. (AVIR) at $4.24 Transaction Date: Jan 31, 2026 | Filing ID: 036281

Read more
2026-02-04 00:47

Vavricka John 🟡 adjusted position in 108.0K shares (3 derivative) of Atea Pharmaceuticals, Inc. (AVIR) at $4.24 Transaction Date: Jan 31, 2026 | Filing ID: 036272

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT06921941 Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and… Phase1 Healthy Volunteer Study Completed 2025-04-08 2025-07-02 ClinicalTrials.gov
NCT06868264 C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic H… Phase3 HEPATITIS C VIRUS CHRONIC INFECTION Active_Not_Recruiting 2025-04-07 2026-12-01 ClinicalTrials.gov
NCT05904470 A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Sub… Phase2 Chronic Hepatitis C Virus Completed 2023-05-30 2025-01-28 ClinicalTrials.gov
NCT05724693 Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function Phase1 Healthy Volunteer Completed 2023-01-30 2024-04-23 ClinicalTrials.gov
NCT05154123 Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998) Phase1 Healthy Volunteer Study Completed 2021-11-16 2021-12-23 ClinicalTrials.gov
NCT04877769 Bronchopulmonary PK of AT-527 (R07496998) Phase1 Healthy Volunteer Study Completed 2021-04-25 2021-08-31 ClinicalTrials.gov
NCT04722627 Study of AT-752 in Healthy Subjects Phase1 Dengue Completed 2021-03-09 2021-11-14 ClinicalTrials.gov
NCT04779242 Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial… Phase3 Community-acquired Pneumonia Completed 2021-02-25 2024-03-27 ClinicalTrials.gov
NCT04709835 Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With… Phase2 COVID-19 Completed 2021-02-03 2021-10-13 ClinicalTrials.gov
NCT03874832 A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injec… Phase1 Migraine With Aura Completed 2018-09-11 2018-11-07 ClinicalTrials.gov
NCT02485249 Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the … Phase1 Macular Edema Terminated 2015-07-01 2016-06-01 ClinicalTrials.gov
NCT01505088 Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic S… Phase3 Anterior Uveitis Completed 2011-12-01 2013-03-01 ClinicalTrials.gov
Total clinical trials: 12
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Citrate buffer DRUG Phase PHASE1 Healthy COMPLETED NCT00698425
EyeGate II® Drug Delivery System OTHER Phase PHASE1 Healthy COMPLETED NCT00698425
Sodium citrate buffer solution with EyeGate® II System DRUG Phase PHASE2 Dry Eye Syndrome COMPLETED NCT00765804
EGP-437 with EyeGate® II System DRUG Phase PHASE2 Dry Eye Syndrome COMPLETED NCT00765804
EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System DRUG Phase PHASE2 Uveitis, Anterior COMPLETED NCT00694135
EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System DRUG Phase PHASE2 Uveitis, Anterior COMPLETED NCT00694135
EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System DRUG Phase PHASE2 Uveitis, Anterior COMPLETED NCT00694135
EGP-437 1.6 mA-min at 0.4 with EyeGate® II System DRUG Phase PHASE2 Uveitis, Anterior COMPLETED NCT00694135
Sodium citrate buffer solution DRUG Phase PHASE3 Dry Eye COMPLETED NCT01129856
Dexamethasone phosphate ophthalmic solution DRUG Phase PHASE3 Dry Eye COMPLETED NCT01129856
Placebo Eyedrops DRUG Phase PHASE3 Anterior Uveitis COMPLETED NCT01505088
100 mM sodium citrate buffer solution DRUG Phase PHASE3 Anterior Uveitis COMPLETED NCT01505088
Prednisolone Acetate (1%) Eyedrops DRUG Phase PHASE3 Anterior Uveitis COMPLETED NCT01505088
40 mg/mL Dexamethasone phosphate ophthalmic solution DRUG Phase PHASE3 Anterior Uveitis COMPLETED NCT01505088
Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA DRUG Phase PHASE1 Patients Having Undergone Unilateral Cataract Extraction and Implantation of a Monofocal COMPLETED NCT02571556
Dexamethasone Phosphate Ophthalmic Solution DRUG Phase PHASE1 Vitrectomy COMPLETED NCT02644694
100 mM Sodium Citrate Buffer DRUG Phase PHASE2 Cataract COMPLETED NCT01602068
Dexamethasone Phosphate Ophthalmic DRUG Phase PHASE1 Macular Edema TERMINATED NCT02485249
Bandage Contact Lens (BCL) DEVICE Approved Ophthalmology COMPLETED NCT03938883
Ocular Bandage Gel (OBG) DEVICE Approved Ophthalmology COMPLETED NCT03938883
Nitrofurantoin capsules DRUG Phase PHASE2 Uncomplicated Urinary Tract Infection COMPLETED NCT03425396
Omadacycline tablets DRUG Phase PHASE2 Uncomplicated Urinary Tract Infection COMPLETED NCT03425396
Levofloxacin DRUG Phase PHASE2 Acute Pyelonephritis COMPLETED NCT03757234
Linezolid DRUG Phase PHASE3 Skin Structures and Soft Tissue Infections WITHDRAWN NCT00876850
PTK 0796 DRUG Phase PHASE3 Skin Structures and Soft Tissue Infections WITHDRAWN NCT00876850
Ocular Bandage Gel DEVICE Approved Corneal Epithelial Wound COMPLETED NCT03163641
Acuvue Oasys DEVICE Approved Corneal Epithelial Wound COMPLETED NCT03163641
Microdialysis Catheter Insertion PROCEDURE Phase PHASE1 Diabetes COMPLETED NCT04144374
Placebos DRUG Phase PHASE3 Migraine COMPLETED NCT03901482
Dihydroergotamine DRUG Phase PHASE1 Migraine With Aura COMPLETED NCT03874832
Omadacycline Oral Tablet [Nuzyra] DRUG Phase PHASE4 Cystic Fibrosis COMPLETED NCT04460586
Omadacycline Injection DRUG Phase PHASE4 Microbial Colonization COMPLETED NCT05515562
Vancomycin Pill DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT06030219
Omadacycline DRUG Phase PHASE3 Bacterial Pneumonia COMPLETED NCT02531438
Omadacycline Oral Tablet DRUG Phase PHASE2 Mycobacterium Infections, Nontuberculous COMPLETED NCT04922554
Omadacycline Injection [Nuzyra] DRUG Phase PHASE4 Cystic Fibrosis COMPLETED NCT04460586
NP-101 DRUG Phase PHASE1 Solid Tumor RECRUITING NCT06563375
Methadone +BEM/RZR DRUG Phase PHASE1 Healthy Volunteer Study NOT_YET_RECRUITING NCT07314346
Buprenorphine/Naloxone + BEM/RZR DRUG Phase PHASE1 Healthy Volunteer Study NOT_YET_RECRUITING NCT07314346
Bemnifosbuvir/Ruzasvir (BEM/RZR) + Ethinyl Estradioll/Levonorgestrel (EE/LNG) DRUG Phase PHASE1 Healthy Volunteer Study NOT_YET_RECRUITING NCT07272889
Bemnifosbuvir/Ruzasvir (BEM/RZR) DRUG Phase PHASE1 Healthy Volunteer Study NOT_YET_RECRUITING NCT07272889
Ethinyl Estradioll/Levonorgestrel (EE/LNG) DRUG Phase PHASE1 Healthy Volunteer Study NOT_YET_RECRUITING NCT07272889
Sofosbuvir-Velpatasvir DRUG Phase PHASE3 HEPATITIS C VIRUS CHRONIC INFECTION RECRUITING NCT07037277
Bemnifosbuvir-Ruzasvir DRUG Phase PHASE3 HEPATITIS C VIRUS CHRONIC INFECTION RECRUITING NCT07037277
Treatment F-Bemnifosbuvir/Ruzasvir FDC administered 2 hours after 40 mg dose Omeprazole DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT07007806
Treatment E-Omeprazole 40 mg administered fasting DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT07007806
Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT07007806
Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT07007806
Treatment B-Omeprazole 20 mg dose administered fasting DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT07007806
Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT07007806
Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT06921941
Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT06921941
Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination DRUG Phase PHASE1 Healthy Volunteer Study RECRUITING NCT06911320
Sofosbuvir-Velpatasvir (SOF/VEL) DRUG Phase PHASE3 HEPATITIS C VIRUS CHRONIC INFECTION ACTIVE_NOT_RECRUITING NCT06868264
Bemnifosbuvir-Ruzasvir (BEM/RZR) DRUG Phase PHASE3 HEPATITIS C VIRUS CHRONIC INFECTION ACTIVE_NOT_RECRUITING NCT06868264
Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT06356194
Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT06356194
Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT06204679
Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT06204679
Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT06204679
Moxifloxacin DRUG Phase PHASE3 Bacterial Pneumonia COMPLETED NCT02531438
Ruzasvir DRUG Phase PHASE2 Chronic Hepatitis C Virus COMPLETED NCT05904470
Bemnifosbuvir DRUG Phase PHASE2 Chronic Hepatitis C Virus COMPLETED NCT05904470
Cohort 2 Ruzasvir + BEM DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT05731843
Cohort 1 BEM + Ruzasvir DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT05731843
Bemnifosbuvir (BEM) DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT05905497
AT-527 and Probenecid DRUG Phase PHASE1 Healthy Volunteer COMPLETED NCT05618314
AT-527 single dose DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT05256732
Placebo Comparator fed OTHER Phase PHASE1 Healthy Volunteer Study COMPLETED NCT05256732
AT-527 fed DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT05256732
Placebo Comparator fasted OTHER Phase PHASE1 Healthy Volunteer Study COMPLETED NCT05256732
AT-527 fasted DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT05256732
AT-527 + rosuvastatin DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT05154123
Drug: AT-527 + rosuvastatin DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT05154123
AT-527 + digoxin DRUG Phase PHASE1 Healthy Volunteers Study COMPLETED NCT05137626
AT-527 (R07496998) DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT05004415
RO7496998 DRUG Phase PHASE3 COVID-19 TERMINATED NCT04889040
AT-527 550 mg + midazolam DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT04865445
AT-527 550 mg + cyclosporine DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT04849299
Period 3: AT-527 1100 mg + carbamazepine DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT04784000
Period 3: AT-527 550 mg + carbamazepine DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT04784000
Period 2: carbamazepine DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT04784000
Period 1: AT-527 550 mg DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT04784000
AT-752 DRUG Phase PHASE2 Dengue Fever TERMINATED NCT05466240
AT-527 Formulation 2 DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT04711187
AT-527 Formulation 1 DRUG Phase PHASE1 Healthy Volunteer Study COMPLETED NCT04711187
Placebo OTHER Phase PHASE2 Cataract COMPLETED NCT03180255
AT-777 DRUG Phase PHASE1 Hepatitis C WITHDRAWN NCT04309734
Daclatasvir DRUG Phase PHASE2 Hepatitis C COMPLETED NCT04019717
Placebo Comparator DRUG Phase PHASE1 Dengue TERMINATED NCT05366439
AT-527 DRUG Phase PHASE1 Healthy Volunteer COMPLETED NCT05618314
Total products: 91